CDH17 and colorectal carcinoma: Therefore, we reckon that the routine, consistent assessment of CDH17 immunohistochemical expression in CRC may become an additional criterion in prognostic evaluation and, at the same time, in the development of therapeutic possibilities, given the current research targeting CDH17 as a potential treatment [31,32,33,34,35].